期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素肽1对糖尿病伴高血压患者血压变异性的影响 被引量：7

Effects of Glucagon Peptide-1 on Blood Pressure Variability in Diabetic Hypertensive Patients
下载PDF
导出
摘要 目的探讨胰高血糖素肽1(GLP-1)对2型糖尿病伴高血压患者血压变异性(BPV)的影响。方法选取糖尿病伴高血压患者120例,使用GLP-1对其进行治疗,检测患者使用前及使用6个月后体质指数(BMI)、空腹血糖、糖化血红蛋白、血清肌酐、血脂等,并进行24 h动态血压监测,得到短时BPV。比较治疗前后的相关指标。结果使用GLP-1后6个月,患者空腹血糖(mmol/L:7.12±0.64 vs 9.19±2.78)、糖化血红蛋白(%:7.00±0.14 vs 8.28±1.32)、BMI(kg/m2:19.30±3.24 vs 24.50±4.53)较治疗前下降(P<0.05),达到控制目标。24 h收缩压(mmHg:135.02±16.57 vs 139.52±15.60)、白昼收缩压(mmHg:132.50±14.60 vs 136.44±14.24)、24 h收缩压变异性(mmHg:12.20±1.44 vs12.73±1.66)、白昼收缩压变异性(mmHg:11.11±1.48 vs 11.74±1.52)、白昼舒张压变异性(mmHg:7.03±1.42 vs 7.43±1.45)也降低(P<0.05)。结论 GLP-1可降低糖尿病伴高血压患者的BPV。 Objective To investigate the role of glucagon peptide-1（GLP-1） in blood pressure variability （BPV） in diabetic hypertensive patients. Methods A total of 120 diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index （BMI）, fasting blood glucose, glycosylated hemoglobin, creatine and 24-hour ambulatory blood pressure （BP） monitoring were detected before and after treatment with GLP-1 for six months. The clinical indices were compared before and after treatment. Results The values of fasting blood glucose （mmol/L：7.12± 0.64 vs 9.19±2.78）, glycosylated hemoglobin （%：7.00±0.14 vs 8.28±1.32） and BMI （kg/m2：19.30±3.24 vs 24.5±4.53 ） were de-creased to the normal level after GLP-1 treatment for six months （P〈0.05）. There were significant decrease in the 24-h sys-tolic BP （mmHg：135.02 ± 16.57 vs 139.52 ± 15.60）, daytime systolic BP （mmHg：132.5 ± 14.6 vs 136.44 ± 14.24）, 24-h systolic BP variability （mmHg：12.20 ± 1.44 vs 12.73 ± 1.66）, daytime systolic BP variability （mmHg：11.11 ± 1.48 vs 11.74 ± 1.52 ）, and daytime diastolic BP variability （mmHg：7.03±1.42 vs 7.43±1.45） after GLP-1 treatment for six months （P〈0.05）. Conclu-sion GLP-1 can decrease BPV in diabetic hypertensive patients.
作者 王少清 臧丽 汪力 高芳 付平
机构地区 成都医学院第一附属医院肾内科 四川大学华西医院肾脏内科
出处 《天津医药》 CAS 北大核心 2014年第8期790-792,共3页 Tianjin Medical Journal
基金 四川省医学会2012年“施慧达”科研课题(SHD12-08)
关键词 胰高血糖素样肽1 糖尿病 2型 高血压 血压变异性 glucagon-like peptide 1 diabetes mellitus, type 2 hypertension blood pressure variability
分类号 R587.1 [医药卫生—内分泌] R544.1 [医药卫生—心血管疾病]
  • 相关文献

参考文献10

  • 1Verdecchia P, Angeli F, Gattobigio R, et al. Impact of blood pres- sure variability on cardiac and cerebrovascular complications in hy- pertension[J]. Am J Hypertens, 2007, 20(2): 154-161.
  • 2Ussher JR, Drucker DJ. Cardiovascular biology of the incretin sys- tem[J].Endocr Rev, 2012,33(2):187-215.
  • 3Zakopoulosa NA, Tsivgoulisb G, Barlas G, et al.Impact of the time rate of blood pressure variation on left ventricular mass[J]. J Hyper tens ,2006,24( 10):2071-2077.
  • 4Poulos NA, Tsivgoulis G, Barlas G, et al. Time rate of blood pres- sure variation is associated with increased common carotid artery in- tima-media thickness[J]. Hypertension, 2005, 45(4):505-512.
  • 5Kesavadev J, Shankar A, Krishnan G, et al.Liraglutide therapy be- yond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting[J].Int J Gen Med,2012,5: 317-322.
  • 6Sander D, Kukla C, Klingelhofer J, et al. Relationship between cir- cadian blood pressure patterns and progression of early carotid ath- erosclerosis A 3-year follow up study[J].Circulation, 2000, 102 (13): 1536-1541.
  • 7Tatasciore A, Renda G, Zinarino M, et al. Awake Systolic blood pressure variability correlates with target organ damage in hyperten- sive subjects[J]. Hypertension, 2007, 50(2): 325-332.
  • 8Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic val- ue of blood pressure variability in the general population[J].Hyper- tension,2007,49(6): 1265-1270.
  • 9Frattola A, Parati G, Castiglioni P, et al. Lacidipine and blood pres- sure variability in diabetic hypertensive patients[J]. Hypertension, 2000,36(4):622-628.
  • 10Masuda S,Tamura K. Effects of angiotensin II type 1 receptor block- er on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy[J]. Hypertens Res, 2009,32(11): 950-955.

同被引文献41

  • 1Ombelli M,Facchetti R,Sega R,et al.Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus,hypertension,and cardiac organ damage[J].Hypertension,2011,58(6):1029-1035.
  • 2Hansen T W,Jeppesen J,Rasmussen S,et al.Ambulatory blood pressure monitoring and risk of cardiovascular disease:a population based study[J].Am J Hypertens,2009,19(3):24330.
  • 3Ussher J R,Drucker O J.Cardiovascular biology of the in cretin system[J].E ndocr Rev,2012,33(2):187-215.
  • 4Miao D M,Ye P,Xiao W K,et al.Influence of low high-density lipoprotein cholesterol on arterial stiffening and left ventricular diastolic dysfunction in essential hypertension[J].J Clin Hypertens(Greenwich),2011,13(10):710-715.
  • 5虞希祥,孟庆建,乔彬彬,等.糖尿病性膝下动脉闭塞症Deep球囊与内科治疗对照研究[J].中国医师杂志,2014,7(15):568-659.
  • 6Escalada FJ. The physiology of glucagon-like peptide-1 and its role inthe pathophysiology of type 2 diabetes mellitus[ J]. Med Clin( Bare),2014’ 143(Suppl 2) : 2-7.
  • 7Ussher JR,Drucker DJ. Cardiovascular biology of the incretin system[J]. Endocr Rev,2012,33(2):187-215. doi:10.1210/er.2011-1052.
  • 8Phillips LK,Prins JB. Update on incretin hormones[J]. Ann N Y AcadSci,2011,1243:E55-74. doi:10.1111/j.1749-6632.2012.06491.x.
  • 9Nystrom T,Gonon AT,Sjoholm A,et al. Glucagon-like peptide-1relaxes rat conduit arteries via an endothelium- independentmechanism[J]. Regul Pept,2005,125(1/3):173-177.
  • 10Golpon H. Effect of GLP- 1 and amylin on lung circulation,thebronchial system and systemic circulation in isolated ex vivo organcultures of the rat[J]. Pneumologie,1998,52(8):439.

引证文献7

二级引证文献9

天津医药
2014年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部